Q-omics provides the consensus-scored PCDHB8 profile across patient tissues and cancer cell-line models. PCDHB8 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, PCDHB8 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, PCDHB8 RNA expression shows 14,387 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, HNSC, and TGCT as cancer lineages where PCDHB8 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PCDHB8 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PCDHB8 survival associations across molecular data types. PCDHB8 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (7) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PCDHB8 RNA expression–survival associations across cancer types. High PCDHB8 expression shows unfavorable associations in BLCA, BRCA, CESC and LUAD, but favorable associations in OV and LAML. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for PCDHB8 RNA expression.
This table summarizes PCDHB8 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PCDHB8. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PCDHB8 shows lower tumor expression in KICH and THCA and higher tumor expression in HNSC, STAD, KIRC and LUSC. The HNSC box plot shows higher PCDHB8 RNA expression in tumor versus normal tissue (log2 FC = +0.836, t-test p < 0.001).
This table shows molecular features associated with PCDHB8 in patient tissues and cancer cell lines. In patient samples, PCDHB8 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PCDHB8 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
